The last patient in Lundbeck’s phase 3 clinical trial, MASCOT, has been randomised ahead of schedule in a study evaluating amlenetug as a potential treatment for multiple system atrophy (MSA). The ...

Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease ...

Currently no disease-modifying or neuroprotective treatments exist for MSA, nor are there effective medications to treat the cerebellar ataxia in MSA-C or the parkinsonian features in MSA-P. Physical ...

Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...

A new study by the University of Turku and Turku University Hospital, Finland, found that a significant proportion of Parkinson's disease diagnoses are later corrected. Up to one in six diagnoses ...

HONOLULU — A novel “moderate-affinity iron chaperone” known as ATH434 (Alterity Therapeutics) may slow disease progression in patients with multiple system atrophy (MSA), new research suggested. The ...

In 2020, Ashley Harms, Ph.D., and University of Alabama at Birmingham colleagues published an Acta Neuropathologica study that used a mouse model to show that the alpha-synuclein pathology from ...

MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...

Alterity Therapeutics has appointed internationally recognised expert in neurodegenerative diseases Daniel O Claassen as chief medical advisor. ... Read More The post Alterity bolsters clinical ...

Final participant randomized to complete enrollment in Phase 1 clinical trial assessing safety of investigational gene therapy AB-1005 delivered to the putamen in patients with multiple system atrophy ...